詳細検索はこちら

横見瀬 裕保 ヨコミセ ヒロヤス

所属
医学部
医学科
職名教授
Last Updated :2020/09/17

研究者基本情報

学歴

  •  - 1992年, 京都大学
  •  - 1992年, 京都大学, 医学研究科
  •  - 1981年, 京都大学
  •  - 1981年, 京都大学, 医学部

学位

  • 医学博士, 京都大学

所属学協会

  • 日本呼吸器外科学会
  • 日本胸部外科学会
  • 日本外科学会

経歴

  •   1996年,  - 1999年, 日本赤十字社和歌山医療センター呼吸器外科, 副部長
  •   1999年, - 香川医科大学, 教授
  •   1991年,  - 1996年, 1991-1996 京都大学 助手, 助手
  •   1991年,  - 1996年, 1991-1996 Kyoto University, Assistant. prof.

研究活動情報

研究分野

  • ライフサイエンス / 呼吸器外科学
  • ライフサイエンス / 心臓血管外科学

研究キーワード

    肺癌, Lung Cancer

論文

  • Anomalous right upper lobe pulmonary veins draining posterior to the pulmonary artery., Otsuki Y, Go T, Chang SS, Matsuura N, Yokomise H, General thoracic and cardiovascular surgery, General thoracic and cardiovascular surgery, 67, (10) 901 - 903,   2019年10月, [査読有り]
  • Lymphatic invasion is a cause of local recurrence after wedge resection of primary lung cancer., Matsuura N, Go T, Fujiwara A, Nakano T, Nakashima N, Tarumi S, Chang SS, Yokomise H, General thoracic and cardiovascular surgery, General thoracic and cardiovascular surgery, 67, (10) 861 - 866,   2019年10月, [査読有り]
  • Correction to: Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery., Hideyuki Shimizu, Shunsuke Endo, Shoji Natsugoe, Yuichiro Doki, Yasutaka Hirata, Junjiro Kobayashi, Noboru Motomura, Kiyoharu Nakano, Hiroshi Nishida, Morihito Okada, Yoshikatsu Saiki, Aya Saito, Yukio Sato, Kazuo Tanemoto, Yasushi Toh, Hiroyuki Tsukihara, Shinji Wakui, Hiroyasu Yokomise, Munetaka Masuda, Kohei Yokoi, Yutaka Okita, General thoracic and cardiovascular surgery, General thoracic and cardiovascular surgery, 67, (6) 573 - 575,   2019年06月, [査読有り]
  • Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery., Hideyuki Shimizu, Shunsuke Endo, Shoji Natsugoe, Yuichiro Doki, Yasutaka Hirata, Junjiro Kobayashi, Noboru Motomura, Kiyoharu Nakano, Hiroshi Nishida, Morihito Okada, Yoshikatsu Saiki, Aya Saito, Yukio Sato, Kazuo Tanemoto, Yasushi Toh, Hiroyuki Tsukihara, Shinji Wakui, Hiroyasu Yokomise, Munetaka Masuda, Kohei Yokoi, Yutaka Okita, General thoracic and cardiovascular surgery, General thoracic and cardiovascular surgery, 67, (4) 377 - 411,   2019年04月, [査読有り]
  • Y-shaped catheter improves carbon dioxide clearance during apnoeic oxygenation in tracheal surgery., Yokota N, Go T, Fujiwara A, Matsuura N, Yokomise H, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,   2019年02月, [査読有り]
  • Thoracic and cardiovascular surgery in Japan during 2015 : Annual report by The Japanese Association for Thoracic Surgery., Munetaka Masuda, Shunsuke Endo, Shoji Natsugoe, Hideyuki Shimizu, Yuichiro Doki, Yasutaka Hirata, Junjiro Kobayashi, Noboru Motomura, Kiyoharu Nakano, Hiroshi Nishida, Morihito Okada, Yoshikatsu Saiki, Aya Saito, Yukio Sato, Kazuo Tanemoto, Yasushi Toh, Hiroyuki Tsukihara, Shinji Wakui, Hiroyasu Yokomise, Kohei Yokoi, Yutaka Okita, General thoracic and cardiovascular surgery, General thoracic and cardiovascular surgery, 66, (10) 581 - 615,   2018年10月, [査読有り]
  • Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer., Fumihiro Tanaka, Hiroyasu Yokomise, Toshinori Soejima, Hidetaka Uramoto, Takeharu Yamanaka, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Yasumasa Nishimura, Hiroshi Niwa, Morihito Okada, Tatsuo Nakagawa, Motohiro Yamashita, The Annals of thoracic surgery, The Annals of thoracic surgery, 106, (4) 1018 - 1024,   2018年10月, [査読有り]
  • Double-barreled bronchoplasty for a carcinoid tumor with a rare variation of displaced bronchus., Matsuura N, Go T, Yokota N, Yokomise H, Journal of thoracic disease, Journal of thoracic disease, 10, (9) E707 - E709,   2018年09月, [査読有り]
  • [Tracheal Injury Successfully Treated without Surgery;Report of a Case]., Ikeda T, Nakano J, Yokomise H, Kyobu geka. The Japanese journal of thoracic surgery, Kyobu geka. The Japanese journal of thoracic surgery, 71, (2) 149 - 151,   2018年02月, [査読有り]
  • Spontaneous torsion of the right upper lung lobe: a case report., Kita Y, Go T, Nii K, Matsuura N, Yokomise H, Surgical case reports, Surgical case reports, 3,   2017年12月, [査読有り]
  • Risk factor of bronchopleural fistula after general thoracic surgery: review article, Masaya Okuda, Tetsuhiko Go, Hiroyasu Yokomise, General Thoracic and Cardiovascular Surgery, General Thoracic and Cardiovascular Surgery, 65, (12) 679 - 685,   2017年12月01日, [査読有り]
  • Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery., Committee for, Scientific Affairs, The Japanese, Association for, Thoracic Surgery, Masuda M, Okumura M, Doki Y, Endo S, Hirata Y, Kobayashi J, Kuwano H, Motomura N, Nishida H, Saiki Y, Saito A, Shimizu H, Tanaka F, Tanemoto K, Toh Y, Tsukihara H, Wakui S, Yokomise H, General thoracic and cardiovascular surgery, General thoracic and cardiovascular surgery, 64, (11) 665 - 697,   2016年11月, [査読有り]
  • Erratum to: Thoracic and cardiovascular surgery in Japan during 2013 : Annual report by The Japanese Association for Thoracic Surgery., Committee for, Scientific Affairs, The Japanese, Association for, Thoracic Surgery, Masuda M, Kuwano H, Okumura M, Arai H, Endo S, Doki Y, Kobayashi J, Motomura N, Nishida H, Saiki Y, Tanaka F, Tanemoto K, Toh Y, Yokomise H, General thoracic and cardiovascular surgery, General thoracic and cardiovascular surgery, 64, (8) 496 - 500,   2016年08月, [査読有り]
  • [Video-assisted Thoracoscopic Segmentectomy Using Infrared Thoracoscopy with Indocyanine Green]., Tarumi S, Yokomise H, Kyobu geka. The Japanese journal of thoracic surgery, Kyobu geka. The Japanese journal of thoracic surgery, 69, (8) 671 - 675,   2016年07月, [査読有り]
  • The impact of certification of general thoracic surgeons on lung cancer mortality: a survey by The Japanese Association for Thoracic Surgery, Takeshi Nagayasua, Shuntaro Sato, Hiroshi Yamamoto, Naoya Yamasaki, Tomoshi Tsuchiya, Keitaro Matsumoto, Takuro Miyazaki, Shunsuke Endo, Fumihiro Tanaka, Hiroyasu Yokomise, Meinoshin Okumura, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 49, (5) E134 - E140,   2016年05月, [査読有り]
  • [Can Pulmonary Rehabilitation during Preoperative Chemoradiotherapy for Non-small Cell Lung Cancer Improve the Respiratory Function?]., Tokunaga Y, Tarumi S, Yokomise H, Kyobu geka. The Japanese journal of thoracic surgery, Kyobu geka. The Japanese journal of thoracic surgery, 69, (1) 47 - 52,   2016年01月, [査読有り]
  • Thoracic and cardiovascular surgery in Japan during 2013: Annual report by The Japanese Association for Thoracic Surgery, Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Munetaka Masuda, Hiroyuki Kuwano, Meinoshin Okumura, Hirokuni Arai, Shunsuke Endo, Yuichiro Doki, Junjiro Kobayashi, Noboru Motomura, Hiroshi Nishida, Yoshikatsu Saiki, Fumihiro Tanaka, Kazuo Tanemoto, Yasushi Toh, Hiroyasu Yokomise, General Thoracic and Cardiovascular Surgery, General Thoracic and Cardiovascular Surgery, 65, (3) 182 - 186,   2015年12月01日, [査読有り]

Misc

  • Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer., Yokomise H, Liu D, Ishikawa S, Go T, Gotoh M, Okuda M, Tarumi S, Kasai Y, Matsuura N, Anticancer Res., 33, (12), 5597-5602,   2013年12月, [査読有り]
  • Surgical treatment of pulmonary aspergilloma and pulmonary cryptococcosis., 横見瀬裕保, Kyobu Geka., 64, (8), 747-751,   2011年07月, [査読有り]
  • 肺癌リンパ節郭清の変遷と現状(解説), 横見瀬裕保, 外科治療, 103, (6), 608-612,   2010年12月, [査読有り]
  • 【診療に役立つ「呼吸器疾患外科治療」のすべて】 肺癌および転移性肺腫瘍 拡大手術 縦隔リンパ節転移に対する郭清, 横見瀬裕保, 日本胸部臨床, 69, 105-111,   2010年09月, [査読有り]
  • Carinoplasty, 横見瀬裕保, Kyobu Geka., 63, (8), 708-711,   2010年07月, [査読有り]
  • Key points in reconstruction of the tracheal bifurcation, 横見瀬裕保, Kyobu Geka, 62, (10), 568-569,   2009年09月, [査読有り]
  • En bloc partial vertebrectomy for lung cancer invading the spine after induction chemoradiotherapy, Hiroyasu Yokomise, Masashi Gotoh, Taku Okamoto, Yasumichi Yamamotoa, Shinya Ishikawa, Dage Liu, Shiro Oka, Cheng-Long Huang, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 31, (5), 788 - 790,   2007年05月, [査読有り]
    Objective: The optimal surgical treatment for non-small cell lung cancer (NSCLC) with vertebral, body invasion remains both controversial and challenging. We reviewed our experiences of NSCLC with vertebral. body invasion, in which we have performed induction chemoradiotherapy followed by lung resection with en bloc partial vertebrectomy. Methods: Six NSCLC patients with vertebral invasion underwent an operation following chemoradiotherapy from January 2001 to July 2006. Vertebral invasion was evaluated by the chest CT and MRI findings. Either carboplatin-paclitaxel (n = 3) or carboplatin-docetaxel (n = 3) was used. Two cycles of chemotherapy were performed with concurrent radiation (50 Gy) treatment. Results: In all of the six cases, a complete resection with en bloc partial vertebrectomy was performed with no operative mortality. The histological complete response rate and major response rate were 16.7% (1/6) and 83.3% (5/6), respectively. The 5-year overall survival rate was 67.7%. In addition, no local failure was observed after surgery. Conclusions: Surgery after chemoradiotherapy (carboplatin/ pactitaxel or docetaxel and 50 Gy radiation) for NSCLC with vertebral invasion could thus be performed with acceptable morbidity. (c) 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer, Hiroyasu Yokomise, Masashi Gotoh, Taku Okamoto, Yasumichi Yamamoto, Shinya Ishikawa, Takashi Nakashima, Daiki Masuya, Dage Liu, Cheng-Long Huang, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 133, (5), 1179 - 1185,   2007年05月, [査読有り]
    Objective: To improve the prognosis of cN2, N3 non-small cell lung cancer, we performed induction chemoradiotherapy (carboplatin-taxane chemotherapy and concurrent 50-Gy radiation) followed by surgery. Methods: Patients with pathologically proven non-small cell lung cancer with bulky cN2, N3 disease were enrolled. forty-one patients underwent an operation after chemoradiotherapy from January 2000 to April 2006. Either carboplatin-paclitaxel (n = 19) or carboplatin- docetaxel (n = 22) chemotherapy was randomly used. Two cycles of chemotherapy were performed with concurrent radiation (50 Gy). In all cases, conventional radiological reevaluations were performed; in the latest 21 cases, reevaluations with positron-emission tomography with fludeoxyglucose F 18 were also performed. Results: In all 41 cases, complete resections were performed, with no operative mortality. The histologically complete response rate, major response rate, and minor response rate were 17.1% (7/41), 56.1% (23/41), and 26.8% (11/41), respectively. The 5-year overall survival was 52.7%. There were no differences in survival between taxane groups. Both the complete response and the major response groups revealed a significantly better 5-year survivals than the minor response group (85.7%, P = 0.44, 52.4%, P = .01). Even with persistent N2 disease, the 5-year survival in the major response group ( 66%) was promising. With the combination of conventional computed tomography and positron-emission tomography with fludeoxyglucose F 18 for reevaluation, eligible patients could be selected for this protocol. Conclusion: Surgery after chemoradiotherapy (carboplatin-taxane and 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer can be safely performed with promising results. Even with persistent N2 disease, the survival in the major response group was promising.
  • Tailor-made chemotherapy for non-small cell lung cancer patients, Cheng-Iong Huang, Hiroyasu Yokomise, Masakazu Fukushima, Moritoshi Kinoshita, Future Oncology, 2, (2), 289 - 299,   2006年04月
    The selection of the most effective chemotherapy treatment based on evaluation of biomarkers, that is, 'tailor-made chemotherapy', can improve the clinical outcome of non-small cell lung cancer patients, including early-stage tumors with a high metastatic potential and advanced-stage tumors with a low proliferation rate. Therefore, treatment would be chosen according to which drugs would be most effective in combating specific tumors. For example: 5-fluorouracil-derived agents would be used for tumors with a low expression of thymidylate synthase gefitinib and erlotinib for tumors with epidermal growth factor receptor (EGFR) mutations or increased EGFR gene copy numbers cisplatin and carboplatin for tumors with a low expression of excision repair cross complementing-1 and gemcitabine for tumors with a low expression of ribonucleotide reductase. The remaining populations of non-small cell lung cancers require chemotherapy using other drugs based on an evaluation of other targeted molecules. © 2006 Future Medicine Ltd.
  • Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor - An expression in non-small-cell lung cancer, CL Huang, D Liu, J Nakano, S Ishikawa, K Kontani, H Yokomise, M Ueno, JOURNAL OF CLINICAL ONCOLOGY, 23, (34), 8765 - 8773,   2005年12月
    Purpose The Writ gene family encodes the multifunctional signaling glycoproteins. We performed the present study to investigate the clinical significance of Wnt5a expression in non-small-cell lung cancer (NSCLC). Patients and Methods One hundred twenty-three patients with NSCLC who had undergone resection were investigated. Real-time quantitative reverse transcriptase polymerase chain reaction was performed to evaluate the Wnt5a gene expression. Immunohistochemistry was performed to investigate the Wnt5a protein expression, the Ki-67 proliferation index, tumor angiogenesis, and the expression of beta-catenin and vascular endothelial growth factor-A (VEGF-A). Results Wnt5a gene expression in squamous cell carcinoma was significantly higher than that in adenocarcinoma (P < .0001). There was a significant correlation between the normalized Wnt5a gene expression ratio and the intratumoral Wnt5a protein expression (r = 0.729; P < .0001). The intratumoral Wnt5a expression was significantly correlated with the Ki-67 proliferation index (r = 0.708; P < .0001). In contrast, no correlation was observed between the intratumoral Wnt5a expression and tumor angiogenesis. Furthermore, the intratumoral Wnt5a expression was significantly correlated with the stromal expression of beta-catenin (r = 0.729; P < .0001) and VEGF-A (r = 0.661; P < .0001). In addition, the stromal VEGF-A expression was also correlated with Ki-67 proliferation (r = 0.627; P < .0001). Cox regression analyses demonstrated Wnt5a status to be a significant prognostic factor for NSCLC patients (P = .0193), especially for patients with squamous cell carcinomas (P = .0491). Conclusion The present study revealed that an overexpression of Wnt5a could produce more aggressive NSCLC, especially in squamous cell carcinomas, during tumor progression.
  • Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer, J Nakano, CL Huang, DG Liu, M Ueno, S Sumitomo, H Yokomise, INTERNATIONAL JOURNAL OF ONCOLOGY, 27, (5), 1215 - 1221,   2005年11月
    Survivin is considered to be associated with tumorigenesis by regulating apoptosis and cell proliferation. Recent experimental studies reported survivin gene expression to be negatively regulated by wild-type p53. We investigated resected tumor specimens from 140 non-small cell lung cancer (NSCLC) patients. Quantitative reverse-transcription PCR analysis was performed to evaluate survivin gene expression. PCR-single strand conformation polymorphism following sequencing was performed to investigate mutations of p53. The apoptotic index and the Ki-67 proliferation index were also evaluated according to the survivin expression. The survivin expression was low in normal lung tissue. In contrast, the survivin expression varied greatly among tumor tissues. The survivin expression in squamous cell carcinomas was significantly higher than that in adenocarcinomas (P=0.0109). The survivin expression in moderately or poorly differentiated tumors was significantly higher than that in well-differentiated tumors (P=0.0334). Furthermore, the survivin expression in tumors with mutant p53 was significantly higher than that in tumors with wild-type p53 (P=0.0026). In addition, the apoptotic index was significantly lower in high-survivin tumors than in low-survivin tumors (P < 0.0001). The Ki-67 proliferation index was significantly higher in high-survivin tumors than in low-survivin tumors (P < 0.0047). This study indicated survivin gene expression to be negatively regulated by p53 in NSCLC, and that survivin expression could inhibit apoptosis and accelerate tumor cell proliferation to produce more aggressive carcinomas.
  • Clinical application of biological markers for treatments of resectable non-small-cell lung cancers, C Huang, D Liu, D Masuya, T Nakashima, K Kameyama, S Ishikawa, M Ueno, R Haba, H Yokomise, BRITISH JOURNAL OF CANCER, 92, (7), 1231 - 1239,   2005年04月
    We performed a clinical study to identify biological markers useful for the treatment of resectable non-small-cell lung cancers (NSCLCs). In all, 173 patients were studied. By immunohistochemistry, we evaluated the Ki-67 proliferation index, tumour vascularity, thymidylate synthase (TS), vascular endothelial growth factor ( VEGF)-A, VEGF-C, and E ( epithelial)-cadherin. Concerning the survival of NSCLC patients, tumour vascularity (P<0.01), VEGF-A status ( P = 0.03), VEGF-C status ( P = 0.03), and E-cadherin status ( P = 0.03) were significant prognostic factors in patients with stage I NSCLCs. The Ki-67 proliferation index ( P = 0.02) and TS status (P<0.01) were significant prognostic factors in patients with stage II - III NSCLCs. In patients with stage II - III NSCLCs, furthermore, the survival of UFT ( a combination of tegafur and uracil)- treated patients with TS-negative tumours was significantly better than those of any other patients. Biological markers associated with tumour angiogenesis or metastasis are useful for the detection of aggressive tumours among early-stage NSCLCs. Postoperative chemotherapy might be necessary in such tumours even in stage I. In contrast, tumour proliferation rate and TS status are useful markers for identifying less aggressive tumours in locally advanced NSCLCs. Thymidylate synthase expression is also a useful marker to evaluate responsiveness of UFT-based chemotherapy for these tumours.
  • MRP-1/CD9 gene transduction downregulates Wnt signal pathways, CL Huang, DG Liu, D Masuya, K Kameyama, T Nakashima, H Yokomise, M Ueno, M Miyake, ONCOGENE, 23, (45), 7475 - 7483,   2004年09月
    Motility-related protein-1 (MRP-1/CD9) is a transmembrane glycoprotein that has been implicated in cell adhesion, motility, proliferation, and differentiation. It has a functional role as a tumor metastatic suppressor. During tumor progression, a reduction of MRP-1/CD9 gene expression results in tumor cells with a high metastatic potential. However, the mechanism of action of MRP-1/CD9 is still unclear. We studied changes of gene expression in relation to MRP-1/CD9 gene transduction into tumor cell lines, HT1080 and A549, using microarray assays and real-time PCR. Consequently, we have demonstrated that MRP-1/ CD9 gene transduction can downregulate expression of several Wnt family genes, such as Wnt1, Wnt2b1 and Wnt5a, and their target genes, including WISP-1 (Wnt-1 induced secreted protein 1), WISP-3, c-Myc, vascular endothelial growth factor-A, and matrix metalloproteinase-26. Western blot analyses also showed that MRP-1/ CD9 gene transduction downregulated expression of Wnt1 protein and its target proteins. In addition, a neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited the downregulation of Wnt signal pathways in MRP-1/CD9-transfected cells. The present study has revealed that the MRP-1/ CD9 signal is located upstream of the Wnt signal pathways. Therefore, MRP-1/ CD9 could suppress cell transformation including epithelial to mesenchymal transition through downregulation of Wnt1, and might suppress tumor metastasis through downregulation of Wnt5a.
  • The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients, D Masuya, C Huang, D Liu, T Nakashima, K Kameyama, R Haba, M Ueno, H Yokomise, BRITISH JOURNAL OF CANCER, 90, (8), 1555 - 1562,   2004年04月
    Immunohistochemical analyses of the effects of hepatocyte growth factor (HGF) and c-Met expression on tumour growth and angiogenesis were performed on 88 patients with non-small-cell lung cancers (NSCLCs). In all, 22 carcinomas (25.0%) were intratumoral HGF-positive, 14 carcinomas (15.9%) were stromal HGF-positive, and 36 carcinomas (40.9%) were intratumoral c-Met-positive. None of the carcinomas were stromal c-Met-positive. Examination of tumour growth revealed that the frequency of tumours with a high Ki-67 index was significantly greater for stromal HGF-positive tumours than for stromal HGF-negative tumours (P = 0.0197). The frequency of tumours with a high Ki-67 index was also significantly greater for intratumoral c-Met-positive tumours than for intratumoral c-Met-negative tumours (P = 0.0301). However, there was no significant difference in tumour vascularity with relation to intratumoral HGF status, stromal HGF status, and intratumoral c-Met status. The survival rate of patients with intratumoral c-Met-positive tumours was significantly lower than for patients with c-Met-negative tumours (P = 0.0095). Furthermore, the survival rate of patients with both intratumoral c-Met-positive and stromal HGF-positive tumours was significantly lower than for patients with either positive tumours, and that of patients with both negative tumours (P = 0.0183 and P = 0.0011, respectively). A univariate analysis revealed that intratumoral c-Met expression was a significant prognostic factor of NSCLC patients (relative risk = 2.642, P = 0.0029). The present study demonstrates that tumour-stromal interaction between tumour cell-derived c-Met and stromal cell-derived HGF affects tumour growth and the prognosis of NSCLC patients.
  • Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer, Med Sci Monit, 10, (6), BR157-BR165,   2004年
  • Neural-cadherin expression associated with angiogenesis in non-small lung cancre patient., Br.J.Cancer, 88, (11), 1727 - 33,   2003年
  • Cartilage regeneration using slow release of bone morphogenetic protein-2 from a gelatin sponge to treat experimental canine tracheomalacia: A preliminary report, T Okamoto, Y Yamamoto, M Gotoh, D Liu, M Kihara, K Kameyama, E Hayashi, K Nakamura, A Yamauchi, CL Huang, H Yokomise, M Yamamoto, T Nakamura, Y Shimizu, Y Tabata, ASAIO JOURNAL, 49, (1), 63 - 69,   2003年01月
    We investigated whether saber sheath-type tracheomalacia could be treated by the slow release of bone morphogenetic protein (BMP)-2 from a gelatin sponge. A 1 cm gap was made in the middle portion of each of 10 consecutive tracheal cartilage rings in the canine cervix (control group, n = 3), then a gelatin sponge containing 12 mug of BMP-2 solution was implanted in the gap (12 mug group, n = 3). In another group (120 mug + P group, n = 3), the implanted gelatin sponge contained 120 mug of BMP-2 solution, and the gap was covered with periosteum. All of the control dogs developed saber sheath-type tracheomalacia, whereas tracheomalacia was not observed in the 12 mug and 120 mug + P groups. In the 12 mug group, fibrous cartilage was observed at the ends of the cartilage stumps. In the 120 mug + P group, newly formed bone and cartilage were observed to form a bridge between the cartilage stumps. The regeneration of cartilage or bone induced by the slow release of BMP-2 from a gelatin sponge might be useful for treatment of tracheomalacia.
  • Recluced INGlb gene expre ssiov plays an important role in carcinogenesis of non-small cell lung cahcer patients., Clinical Cancer Research, 9, (13), 4926 - 4934,   2003年
  • Neural-cadherin expression associated with angiogenesis in non-small lung cancre patient., Br.J.Cancer, 88, (11), 1727 - 33,   2003年
  • Cartilage regeneration using slow release of bone morphogenetic protein-2 from a gelatin sponge to treat experimental canine tracheomalacia: A preliminary report, T Okamoto, Y Yamamoto, M Gotoh, D Liu, M Kihara, K Kameyama, E Hayashi, K Nakamura, A Yamauchi, CL Huang, H Yokomise, M Yamamoto, T Nakamura, Y Shimizu, Y Tabata, ASAIO JOURNAL, 49, (1), 63 - 69,   2003年01月
    We investigated whether saber sheath-type tracheomalacia could be treated by the slow release of bone morphogenetic protein (BMP)-2 from a gelatin sponge. A 1 cm gap was made in the middle portion of each of 10 consecutive tracheal cartilage rings in the canine cervix (control group, n = 3), then a gelatin sponge containing 12 mug of BMP-2 solution was implanted in the gap (12 mug group, n = 3). In another group (120 mug + P group, n = 3), the implanted gelatin sponge contained 120 mug of BMP-2 solution, and the gap was covered with periosteum. All of the control dogs developed saber sheath-type tracheomalacia, whereas tracheomalacia was not observed in the 12 mug and 120 mug + P groups. In the 12 mug group, fibrous cartilage was observed at the ends of the cartilage stumps. In the 120 mug + P group, newly formed bone and cartilage were observed to form a bridge between the cartilage stumps. The regeneration of cartilage or bone induced by the slow release of BMP-2 from a gelatin sponge might be useful for treatment of tracheomalacia.
  • Recluced INGlb gene expre ssiov plays an important role in carcinogenesis of non-small cell lung cahcer patients., Clinical Cancer Research, 9, (13), 4926 - 4934,   2003年
  • Problems related to TNM Staging: patients with stage Ⅲ non-small cell lung cancer, J. Thorac. Cardiovasc. Surg, 124, (3), 503 - 510,   2002年09月
  • Problems related to TNM staging: Patients with stage III non-small cell lung cancer, K Kameyama, CL Huang, DG Liu, T Okamoto, E Hayashi, Y Yamamoto, H Yokomise, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 124, (3), 503 - 510,   2002年09月
    Objective: Many reports have raised certain problems concerning the current TNM classification of lung cancer, namely that there is no sufficient difference in prognosis between patients with pathologic stage IIIA and IIIB disease. For clarifying this problem, the present study was constructed in light of T3 and T4 classifications. Methods: Among 429 patients with non-small cell lung cancer who underwent resection, those with stage IIIA (n = 73) and stage IIIB (n = 79) disease were enrolled in this study, and their prognostic factors were compared. Results: No difference in the survivals between patients with T3 and T4 disease was observed, and this seemed to affect the prognoses of patients with stage IIIA and IIIB disease. However, when those with T3 and T4 disease were classified into different groups on the basis of TNM descriptors, differences in the survivals became evident. The T3 bronchial invasion group showed a better prognosis than the T3 extrapulmonary invasion group. The T4 tracheal invasion group and T4 pulmonary metastasis group showed a significantly better prognosis than that in the T4 extrapulmonary invasion group and the T4 malignant pleural exudate group. The surgical curativity of patients with T3 disease was evaluated as curative resection or noncurative resection, and the surgical curativity of T4 was evaluated as R0 resection or R1 or R2 resection. The T3 bronchial invasion group included more curative resection cases. The T4 tracheal invasion group and T4 pulmonary metastasis group included more R0 resection cases. Furthermore, when patients with T3 to T2 bronchial invasion and patients with T4 tracheal invasion and T4 pulmonary metastasis were reclassified as having T3 disease, the survivals of the patients reclassified as having T3 and T4 disease, as well as the resultant subsets having stage IIIA and IIIB disease, were significantly different. Conclusion: Tumor status should be reviewed by taking into account the surgical curativity.
  • Topoisomerase Ⅱα gene expression is regulated by the p53 Tumor suppressor gene in non small cell lung carcinoma patients., Cancer, 94, (8), 2239 - 2247,   2002年04月
  • Topoisomerase II alpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients, DG Liu, CL Huang, K Kameyama, E Hayashi, A Yamauchi, S Sumitomo, H Yokomise, CANCER, 94, (8), 2239 - 2247,   2002年04月
    BACKGROUND. Topoisomerase IIalpha (Topo IIalpha) is an essential nuclear enzyme for chromosome segregation during mitosis. Previous experimental studies using cell lines reported that Topo IIalpha expression was negatively regulated by wild-type p53 through the gene's promoter region. METHODS. Surgically resected tumor specimens from 98 nonsmall cell lung carcinoma (NSCLC) patients who were not treated with preoperative chemotherapy were studied. Quantitative reverse-transcription polymerase chain reaction analysis was done to evaluate Topo IIalpha gene expression. Polymerase chain reaction single strand conformation polymorphism following sequencing was performed to investigate mutations of p53. RESULTS. Topo IIalpha gene expression in squamous cell carcinomas was significantly higher than in adenocarcinomas (P = 0.0007). Topo IIalpha gene expression in moderately differentiated tumors and poorly differentiated tumors was significantly higher than in well differentiated tumors (P = 0.0032 and P = 0.0005, respectively). Thirty nine tumors (40%) had mutations of p53. Topo IIalpha gene expression in tumors with mutant p53 was significantly higher than in those with wild-type p53 (P = 0.0224). CONCLUSIONS. The current study suggests that Topo IIalpha gene expression is regulated by p53 gene status in NSCLC patients and that the overexpression of Topo IIalpha induced by mutant p53 might cause more aggressive carcinogenesis. 9 2002 American Cancer Society.
  • Induction chermetherapy before operation for maltiple endobronchial squamous cell carcinoma of the lung., Ann. Thorac. Surg., 74, 1008 - 10,   2002年
  • Induction chermetherapy before operation for maltiple endobronchial squamous cell carcinoma of the lung., Ann. Thorac. Surg., 74, 1008 - 10,   2002年
  • E-cadherin expression associated with differentiation and prognosis in natients with non small cell lung cancer, Ann. Thorac. sung., 71, (3), 949 - 55,   2001年
  • The intratumoral expression of vascular endothelial growth factor and inter lenkin-8 associated with angiogenesis in non small cell lung carcinoma patients, cancer, 92, (10), 2628 - 38,   2001年
  • E-cadherin expression associated with differentiation and prognosis in natients with non small cell lung cancer, Ann. Thorac. sung., 71, (3), 949 - 55,   2001年
  • The intratumoral expression of vascular endothelial growth factor and inter lenkin-8 associated with angiogenesis in non small cell lung carcinoma patients, cancer, 92, (10), 2628 - 38,   2001年
  • Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-base chemotherapy. Int J Oncol 17: 47-54, 2000, Int J Oncol, 17, 47 - 54,   2000年

書籍等出版物

  • 結核, 医学書院,   2006年
  • CT diagnosis of respiratory diseases,   2006年
  • 新臨床外科学, 医学書院,   2006年
  • 呼吸器診療のコツと落とし穴, 中山書店,   2005年

講演・口頭発表等

  • Biomarkers as Prognostics Factors for cN2,3 Non-Small Cell Lung Cancer Treated by Induction Chemoradiotherapy and Surgery, STS 48th Annual Meeting,   2012年
  • バイオマーカーを用いたcN2,3非小細胞肺癌に対する術前化学放射線療法に向けて, 第111回日本外科学会定期学術集会,   2011年
  • 第77回卒後教育セミナー「リンパ郭清の昔と今:肺癌」, 第110回日本外科学会定期学術集会,   2010年
  • 「外科と化学療法」 -呼吸器-, 第18回日本外科学会生涯教育セミナー,   2010年
  • 第18回日本外科学会生涯教育セミナー「外科と化学療法」, 第85回中国四国外科学会総会,   2010年
  • 進行肺癌に対する導入療法・補助化学療法, 第23回冬季札幌がんセミナー,   2009年
  • 進行非小細胞肺癌に対する術前化学放射線療法, 第239回徳島呼吸器疾患談話会,   2009年
  • 術前化学療法, 第15回呼吸器外科セミナー,   2009年
  • 開胸下肺葉切除, 第52回関西胸部外科学会学術集会,   2009年
  • 肺癌の個別化治療における外科の役割, 第47回日本癌治療学会学術集会,   2009年
  • 悪性胸膜中皮腫に対する集学的治療の現況 悪性胸膜中皮種に対する集学的治療の試み, 第33回日本外科系連合学会学術集会,   2008年
  • 肺非小細胞癌における術前化学療法の最新知見, Hiroshima Lung Cancer Seminar 2008,   2008年
  • 外科から見た進行肺癌の治療, 第49回日本肺癌学会総会,   2008年
  • 外科治療(進行肺癌), 第49回日本肺癌学会総会,   2008年
  • 非小細胞肺癌における腫瘍内Wnt5a発現とtumor-stromal interaction, 第106回日本外科学会定期学術集会,   2006年
  • 非小細胞肺癌におけるバイオマーカーに基づいた個別化アジュバント化学療法, 第23回日本呼吸器外科学会総会,   2006年
  • Wnt signal pathways are down-regulated by MRP-1/CD9 gene transduction, 96th Annual Meeting of American Association for Cancer Research,   2005年
  • 分子マーカーに基づく非小細胞肺癌の治療戦略, 第22回日本呼吸器外科学会総会,   2005年
  • MRP-1/CD9遺伝子導入によるWntシグナル抑制, 第64回日本癌学会学術総会,   2005年
  • 分子マーカーに基づいた非小細胞肺癌のオーダーメイド化学療法, 第58回日本胸部外科学会定期学術集会,   2005年
  • Clinical application of biological markers for treatments of non-small cell lung cancer patients, 9th World Congress on Advances in Oncology,   2004年

作品

  • MK-0683(全身化学療法の治療歴がある進行性悪性胸膜中皮腫患者を対象とした)MK-0683の無作為化、二重盲検、プラセボ対象第Ⅲ相試験,   2009年  - 2011年

競争的資金

  • 再生医学,   1999年
  • Regenerative Medicine,   1999年
  • Regenerative Medicine,   1999年
  • 肺移植,   1988年 - 1996年
  • Lung Transplantation,   1988年 - 1996年
  • Lung Transplantation,   1988年 - 1996年
  • 気管移植,   1988年
  • Tracheal Transplantation,   1988年
  • 肺癌の外科治療,   1988年
  • Surgery for Lung Cancer,   1988年
  • Tracheal Transplantation,   1988年
  • Surgery for Lung Cancer,   1988年